Clinical studies with drugs and biologics aimed at slowing or reversing normal aging processes—emerging results and future perspectives
Five families of investigational products are in clinical investigation to slow or reverse normal aging processes [longevity candidates, mesenchymal stem cells, senolytics drugs, sirtuin activators, and nicotinamide adenine dinucleotide (NAD)+ precursors]. The longevity candidates, vitamin D and met...
Saved in:
Main Author: | Ricardo P. Garay |
---|---|
Format: | Article |
Language: | English |
Published: |
Open Exploration
2024-04-01
|
Series: | Exploration of Drug Science |
Subjects: | |
Online Access: | https://www.explorationpub.com/uploads/Article/A100840/100840.pdf |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Frailty in older adults admitted to hospital: outcomes from the Western Sydney Clinical Frailty Registry
by: Julee McDonagh, et al.
Published: (2025-02-01) -
Advances in regenerative medicine-based approaches for skin regeneration and rejuvenation
by: Nathalia Silva Dutra Alves, et al.
Published: (2025-02-01) -
Development of a psychological frailty index: results from the China health and retirement longitudinal study
by: Jinlong Zhao, et al.
Published: (2025-02-01) -
Smart natural technology & maintenance of sustainable aquatic environment: A study during lockdown
by: Sucharita Bhattacharyya, et al.
Published: (2025-03-01) -
Microbiome transplants may not improve health and longevity in Drosophila melanogaster
by: Benjamin H. Levine, et al.
Published: (2025-01-01)